Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →CD11c(+) T-Bet(+) B Cell Expansion Reveals a Distinct Pathogenic Signature in Autoimmune Liver Diseases.
Clinical takeawayNo clinical action yet: a mechanistic finding in human blood samples identifying distinct immune signatures in AIH and AIH/PBC overlap. Potential therapeutic implications for targeting pathogenic B cell subsets remain investigational.
What it foundCD11c+T-bet+ B cells were significantly expanded in AIH (n=15) and AIH/PBC overlap (n=11) but not in PBC (n=8), with increased cTfh cells and higher IL-21 levels in non-responders.
ContextChallenges the traditional T cell-driven model of autoimmune liver diseases by highlighting B cell alterations, particularly in AIH and AIH/PBC overlap, which may refine disease classification and therapeutic strategies.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases, 'Primary Biliary Cholangitis: 2021 Practice Guidance', 2021
Decision at stakethe potential for targeted B-cell therapies in autoimmune liver diseases
American Association for the Study of Liver Diseases, 'Primary Biliary Cholangitis: 2021 Practice Guidance', 2021 · reviewed 2026-07-21 ↗Treat with first-line ursodeoxycholic acid (UDCA) 13-15 mg/kg/d divided, and assess biochemical response at 12 months using Paris-II plus continuous risk scores (Globe, UK-PBC). Escalate to a second-line agent (obeticholic acid [contraindicated in cirrhosis with portal hypertension or prior decompensation], seladelpar, elafibranor, or a fibrate) when response is inadequate, guided by a Child-Pugh/portal-hypertension hard gate, and manage pruritus with a stepwise ladder (cholestyramine → rifampin → sertraline → naltrexone). Refer for transplant evaluation for decompensation, refractory pruritus, or rising bilirubin.
D'Orso S … Cardinale V · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗